^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MGD024

    i
    Company:
    Gilead, MacroGenics
    Drug class:
    CD3 agonist, CD123 inhibitor
    Related drugs:
    Apply
    A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies (CP-MGD024-01) (NCT05362773)
    Phase 1
    MacroGenics
    Recruiting
    Last update posted :
    01/17/2024
    Initiation :
    07/13/2022
    Primary completion :
    03/01/2025
    Completion :
    03/01/2025
    IL3RA
    |
    CD123 expression • IL3RA expression
    |
    MGD024